Clarity Pharmaceuticals Company Description
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States.
The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.
It develops theranostic therapy and imaging products for the treatment of cancer in children and adults.
The company was incorporated in 2010 and is based in Sydney, Australia.
| Country | Australia |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Michelle Parker |
Contact Details
Address: National Innovation Centre Sydney, 2015 Australia | |
| Phone | 61 2 9209 4037 |
| Website | claritypharmaceuticals.com |
Stock Details
| Ticker Symbol | CLRPF |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michelle Parker | Chief Executive Officer, MD and Executive Director |
| Dr. Alan John Taylor Ph.D. | Executive Chairman |
| David K. Green BEc., CA | Chief Financial Officer |
| Dr. Colin David Biggin Ph.D. | Chief Operating Officer and Non-Independent Executive Director |
| Dr. Matthew Harris BSc., M.B.A., Ph.D. | Chief Scientific Officer |
| Lisa Sadetskaya | Director of Corporate Communications. |
| Mary Bennett | Head of People and Culture |
| Shaemus Gleason | Executive Vice President of Operations |
| Dr. Othon Gervasio | Chief Medical Officer |
| Eva Lengyelova | Executive Vice President of Clinical Development |